Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Krensavage Asset Management, LLC

Q3 2023 · 13F-HR

Krensavage Asset Management, LLCholdings as filed

Filed 2023-11-15 · accession 0001609251-23-000005

$271,606
Reported value
12
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
91307C102UTHRUNITED THERAPEUTICS CORP$45,45016.7%201,222CommonSOLE
30161Q104EXELEXELIXIS INC$41,49615.3%1,899,151CommonSOLE
09062X103BIIBBIOGEN INC$41,24515.2%160,480CommonSOLE
75886F107REGNREGENERON PHARMACEUTICALS$38,89014.3%47,256CommonSOLE
G01767105ALKSALKERMES PLC$25,3799.34%906,060CommonSOLE
14149Y108CAHCARDINAL HEALTH INC$25,2929.31%291,319CommonSOLE
M8737E108TARO PHARMACEUTICAL INDUS$24,1628.90%640,735CommonSOLE
29082K105EMBCEMBECTA CORP$17,5316.45%1,164,876CommonSOLE
29251M106ENTAENANTA PHARMACEUTICALS INC$8,2113.02%735,103CommonSOLE
269796108EGRXEAGLE PHARMACEUTICALS INC$1,7770.65%112,666CommonSOLE
921659108VNDAVANDA PHARMACEUTICALS INC$1,5570.57%360,429CommonSOLE
50015M109KODKODIAK SCIENCES INC$6160.23%342,312CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.